Do mantle cell lymphomas have an 'Achilles heel'?

Current Opinion in Hematology

Volumn 21, Issue 4, 2014, Pages 350-357

  Saba, Nakhle ^a   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

B cell lymphoma 2; B cell receptor; Cyclin D1; Ibrutinib; Mantle cell lymphoma

Indexed keywords

ATM PROTEIN; AURORA KINASE INHIBITOR; B LYMPHOCYTE RECEPTOR; BIM PROTEIN; CYCLIN D1; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BIRC3; PROTEIN MCL 1; PROTEIN P53; PROTEIN UBR5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; VENETOCLAX;

3' UNTRANSLATED REGION; APOPTOSIS; B CELL LYMPHOMA; B CELL LYMPHOMA 2; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL SURVIVAL; DNA DAMAGE; DNA REPLICATION; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SOMATIC MUTATION; SYSTEMATIC REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; DRUG EFFECTS; LYMPHOMA, MANTLE-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

CYCLIN D1; DNA DAMAGE; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84902258028     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000057     Document Type: Review

References (61)

1. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122:3416-3423.
2. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117:26-38.
3. Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013; 110:18250-18255.
4. Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biological and clinical features. Cancer Res 2012; 72:5307-5316.
5. Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119:4215-4223.
6. Vegliante MC, Palomero J, Pérez-Galán P, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013; 121:2175-2185.
7. Vose JM. Mantle cell lymphoma: 2013 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2013; 88:1082-1088.
8. Rivera-Rodriguez N, Cabanillas F. Recent advances in the management of mantle cell lymphoma. Curr Opin Oncol 2013; 25:716-721.
9. Smith MR. Is early hematopoietic stem-cell transplantation necessary in mantle-cell lymphoma? J Clin Oncol 2014; 32:265-267.
10. Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29:3023-3029.
11. Li ZM, Zucca E, Ghielmini M. Open questions in the management of mantle cell lymphoma. Cancer Treat Rev 2013; 39:602-609.
12. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007; 109:4599-4606.
13. Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 2012; 97:1422-1430.
14. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22:2097-2105.
15. Jones JA, Rupert AS, Poi M, et al. Flavopiridol can be safelyadministered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkins lymphoma. Am J Hematol 2014; 89:19-24.
16. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597-4607.
17. Spurgeon SEF, Wagner-Johnston ND, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL). ASCO Meeting Abstracts 2013; 31:8519.
18. Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-1091.
19. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-516.
20. Davids MS, Seymour JF, Gerecitano JF, et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood 2013; 122:1789.
21. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014; 32:44-50.
22. Chiron D, Martin P, Di Liberto M, et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle 2013; 12:1892-1900.
23. Martin P, DiLiberto M, Mason CE, et al. The combination of palbociclib plus bortezomib is safe and active in patients with previously treated mantle cell lymphoma: final results of a phase I trial. Blood 2013; 122:4393.
24. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014; 24:71-81.
25. Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013; 27:173-206.
26. Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 2013; 119:1570-1577.
27. Xargay-Torrent S, Lopez-Guerra M, Montraveta A, et al. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. Clin Cancer Res 2013; 19:586-597.
28. Saba NS, Liu D, Herman SEM, et al. Gene expression profiling reveals the lymph node microenvironment as a niche for BCR engagement, NFkB pathway activation, and tumor proliferation in mantle cell lymphoma. Blood 2013; 122:82.
29. Perez-Galan P, Mora-Jensen H, Weniger MA, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011; 117:542-552.
30. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011; 118:3088-3095.
31. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117:563-574.
32. Myklebust JH, Brody J, Alizadeh AA, et al. Potentiated B-cell antigen receptor signaling in mantle cell lymphoma is associated with overexpression of surface CD79B and IgM. Blood 2013; 122:1768.
33. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23:410-421.
34. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117:6287-6296.
35. Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res 2013; 37:1271-1277.
36. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463:88-92.
37. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88-94.
38. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42.
39. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Brutons tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013; 31:128-130.
40. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-3829.
41. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115:2578-2585.
42. Iyengar S, Clear A, Bödör C, et al. P110a-mediated constitutive PI3K signaling limits the efficacy of p110d-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013; 121:2274-2284.
43. Horwitz SM, Flinn I, Patel MR, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed/refractory lymphoma. ASCO Meeting Abstracts 2013; 31:8518.
44. Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 2014; 99:7-18.
45. Rahal R, Frick M, Romero R, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014; 20:87-92.
46. Wilson WH, OConnor OA, Czuczman MS, et al. Navitoclax, a targeted highaffinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149-1159.
47. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30:488-496.
48. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-208.
49. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell 2013; 23:139-141.
50. Touzeau C, Brosseau C, Dousset C, et al. Mantle-cell lymphoma (MCL) cells are highly sensitive to ABT-199 but their sensitivity may be altered by the microenvironment via the up-regulation of Bcl-Xl and Bcl2A1. Blood 2013; 122:4285.
51. Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012; 120:3501-3509.
52. Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model. Blood 2013; 122:645.
53. Villamor N, Lopez-Guillermo A, Lopez-Otin C, Campo E. Next-generation sequencing in chronic lymphocytic leukemia. Semin Hematol 2013; 50:286-295.
54. Starczynski J, Simmons W, Flavell JR, et al. Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. Am J Pathol 2003; 163:423-432.
55. Meissner B, Kridel R, Lim RS, et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013; 121:3161-3164.
56. Gudjonsson T, Altmeyer M, Savic V, et al. TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell 2012; 150:697-709.
57. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-698.
58. Williamson CT, Kubota E, Hamill JD, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012; 4:515-527.
59. Schwartz GK, Carvajal R, Fury M, et al. ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma. Blood 2013; 122:4366.
60. Mahadevan D, Stejskal A, Cooke LS, et al. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012; 18:2210-2219.
61. Kelly KR, Persky DO, Mahadevan D, et al. Phase 1 study of investigational agent MLN8237 (alisertib) + rituximab + vincristine in patients (pts) with relapsed/refractory (Rel/Ref) aggressive B-cell lymphomas. Blood 2013; 122:3027.